To characterize the safety and tolerability of the brequinar-dipyridamole combination in COVID-19 subjects as measured by frequencies of grade 3 and 4 toxicities and serious adverse events (SAEs) considered by the investigator to be related to the combination.Timepoint: qPCR SARS-CoV-2 levels through Day 29 and at days 4; 8; 12; 15; 22; and 29 <br/ >

To characterize the safety and tolerability of the brequinar-dipyridamole combination in COVID-19 subjects as measured by frequencies of grade 3 and 4 toxicities and serious adverse events (SAEs) considered by the investigator to be related to the combination.Timepoint: qPCR SARS-CoV-2 levels through Day 29 and at days 4; 8; 12; 15; 22; and 29 <br/ >